The preclinical results of AB-106, an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology Co., Ltd. from Daiichi Sankyo Company, Limited, were published online by the peer-reviewed academic journal Nature Communications on August 9, 2019.[1]
September 25, 2019
· 3 min read